Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults

Clinical and Vaccine Immunology

Volumn 15, Issue 2, 2008, Pages 253-259

  Durando, P ^a,d   Fenoglio, D ^b   Boschini, A ^c   Ansaldi, F ^a   Icardi, G ^a   Sticchi, L ^a   Renzoni, A ^a   Fabbri, P ^c   Ferrera, A ^b   Parodi, A ^d   Bruzzone, B ^a   Gabutti, G ^e   Podda, A ^f   Del Giudice, G ^f   Fragapane, E ^f   Indiveri, F ^b   Crovari, P ^a   Gasparini, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c San Patrignano Medical Centre   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EVALUATION; FEMALE; FEVER; GEOMETRY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INDURATION; SWEATING; VIREMIA; ADOLESCENT; AGED; BLOOD; CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HIV INFECTIONS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; VACCINES, SUBUNIT; VIREMIA;

EID: 40449113207     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00316-07     Document Type: Article

References (53)

1. Amendola, A., A. Boschini, D. Colzani, G. Anselmi, A. Oltolina, and R. Zucconi. 2001. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J. Med. Virol. 65:644-648.
2. Ansaldi, F., G. Icardi, R. Gasparini, C. Campello, S. Puzelli, A. Bella, I. Donatelli, S. Salmaso, and P. Crovari. 2005. New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season. J. Clin. Microbiol. 43:3027-3029.
3. Baldo, V., T. Baldovin, A. Floreani, A. M. Carraro, R. Trivello, and Family Medicine Group of Pianiga. 2007. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25:3955-3961.
4. Baldo, V., T. Baldovin, A. Floreani, E. Fragapane, R. Trivello, and The Family Medicine Group. 21 May 2007. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J. Clin. Immunol. doi:10.1007.s10875-007-9100-4.
5. Baldo, V., T. Menegon, C. Bonello, A. Floreani, R. Trivello, and "Mariutto" Collaborative Group. 2001. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19:3472-3475.
6. Barker, W. H. 1986. Excess pneumonia and influenza associated hospital-ization during influenza epidemics in the United States, 1970-78. Am. J. Public Health 76:761-765.
7. Beyer, W. E., A. M. Palache, G. Luchters, J. Nauta, and A. D. Osterhaus. 2004. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res. 103:125-132.
8. Boschini, A., B. Longo, F. Caselli, M. Begnini, C. De Maria, F. Ansaldi, P. Durando, G. Icardi, and G. Rezza. 2006. An outbreak of influenza in a residential drug-rehabilitation community. J. Med. Virol. 78:1218-1222.
9. Clements, M. L., and I. Stephens. 1997. New and improved vaccines against influenza, p. 545-570. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines, 2nd ed. Marcel Dekker, New York, NY.
10. Couch, R. B. 1999. Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin. Infect. Dis. 28:548-551.
11. de Bruijn, I. A., J. Nauta, L. Gerez, and A. M. Palache. 2004. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res. 103:139-145.
12. De Carvalho, A. P., L. C. Dutra, and E. Tonelli. 2003. Influenza vaccination in HIV infected children: immunologic and viral changes. J. Pediatr. 79:29-40. (In Portuguese.)
13. De Donato, S., D. Granoff, M. Minutello, G. Lecchi, M. Faccini, M. Agnello, F. Senatore, P. Verveij, B. Fritzell, and A. Podda. 1999. Safety and immu-nogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17:3094-3101.
14. Dowle, W. R., A. P. Kendal, and G. R. Noble. 1979. Influenza viruses, p. 585-590. In E. M. Lennette and N. J. Schmidt (ed.), Diagnostic procedures for viral rickettsial and chlamydial infections, 5th ed. American Public Health Association, Washington, DC.
15. Evans, K. D., and M. W. Kline. 1995. Prolonged influenza A infection responsive to rimantidine therapy in a human immunodeficiency virus-infected child. Pediatr. Infect. Dis. J. 14:332-334.
16. Frey, S., G. Poland, S. Percell, and A. Podda. 2003. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21: 4234-4237.
17. Gabutti, G., M. Guido, P. Durando, A. De Donno, M. Quattrocchi, S. Bacilieri, F. Ansaldi, S. Cataldini, P. G. Chiriaco, M. De Simone, S. Minniti, L. Sticchi, and R. Gasparini. 2005. Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients. J. Int. Med. Res. 33:406-416.
18. Gasparini, R., C. Lucioni, P. Lai, P. Maggioni, L. Sticchi, P. Durando, P. Morelli, I. Comino, S. Calderisi, and P. Crovari. 2002. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 20(Suppl. 5):B50-B54.
19. Gasparini, R., T. Pozzi, E. Montomoli, E. Fragapane, F. Senatore, M. Minutello, and A. Podda. 2001. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17:135-140.
20. Givan, A. L., J. L. Fisher, M. Waugh, M. S. Ernstoff, and P. K. Wallace. 1999. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J. Immunol. Methods 230:99-112.
21. Glezen, W. P., S. B. Greenberg, R. L. Atmar, P. A. Piedra, and R. B. Couch. 2000. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283:499-505.
22. Glück, R., and A. Wegman. 1997. Influenza vaccination in the elderly. Dev. Comp. Immunol. 21:501-507.
23. Günthard, H. F., J. K. Wong, C. A. Spina, C. Ignacio, S. Kwok, C. Christo-pherson, J. Hwang, R. Haubrich, D. Havlir, and D. D. Richman. 2000. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J. Infect. Dis. 181:522-531.
24. Iorio, A. M., D. Francisci, B. Camilloni, G. Stagni, M. De Martino, and D. Toneatto. 2003. Antibody responses and HIV-1 viral load in HIV-1-seropos-itive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active anti-retroviral therapy. Vaccine 21:3629-3637.
25. Kroneman, M., G. A. van Essen, and W. J. Paget. 2006. Influenza vaccination coverage and reasons to refrain among high-risk persons in four European countries. Vaccine 24:622-628.
26. Kroon, F. P., J. T. van Dissel, J. C. de Jong, K. Zwinderman, and R. van Furth. 2000. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 18:3040-3049.
27. Lin, J. C., and K. L. Nichol. 2001. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch. Intern. Med. 161:441-446.
28. Mazza, J. J., S. H. Yale, J. R. Arrowood, C. E. Reynolds, I. Glurich, P. H. Chyou, J. G. Linneman, and K. D. Reed. 2005. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin. Med. Res. 3:214-220.
29. McElhaney. J. E., D. Xie, W. D. Hager, M. B. Barry, Y. Wang, A. Kleppinger, C. Ewen, K. P. Kane, and R. C. Bleackley. 2006. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176:6333-6339.
30. Meijer, A., W. J. Paget, T. J. Meerhoff, C. S. Brown, L. E. Meuwissen, J. van der Velden, and the European Influenza Surveillance Scheme (EISS). 2006. Epidemiological and virological assessment of influenza activity in Europe, during the 2004-2005 winter. Euro Surveill. 11:111-118.
31. Minutello, M., F. Senatore, G. Cecchinelli, M. Bianchi, T. Andreani, A. Podda, and P. Crovari. 1999. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17:99-104.
32. Mullooly, J. P., M. D. Bennett, M. C. Hornbrook, W. H. Barker, W. W. Williams, P. A. Patriarca, and P. H. Rhodes. 1994. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann. Intern. Med. 121:947-952.
33. Neuzil, K. M., G. W. Reed, E. F. Mitchel, Jr., and M. R. Griffin. 1999. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 281:901-907.
34. Nordin, J., J. Mullooly, S. Poblete, R. Strikas, R. Petrucci, F. Wei, B. Rush, B. Safirstein, D. Wheeler, and K. L. Nichol. 2001. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J. Infect. Dis. 184:665-670.
35. O'Brien, W. A., K. Grovit-Ferbas, A. Namazi, S. Ovcak-Derzic, H. J. Wang, J. Park, C. Yeramian, S. H. Mao, and J. A. Zack. 1995. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86:1082-1089.
36. O'Hagan, D. T. 2007. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6:699-710.
37. Paschke, R., M. Pollok, H. Geiger, M. Ketteler, D. Abendroth, and M. Gunther. 2003. Increased immunogenicity with an MF59-adjuvanted influenza vaccine compared to a conventional sub-unit vaccine in renal transplant recipients. J. Prev. Med. Hyg. 44:79-84.
38. Podda, A. 2001. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59 adjuvanted vaccine. Vaccine 19:2673-2680.
39. Radwan, H. M., S. H. Cheeseman, K. K. Lai, and R. T. Ellison III. 2000. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin. Infect. Dis. 31:604-606.
40. + individuals. Clin. Exp. Immunol. 104:203-207.
41. Skiest, D. J., and T. Machala. 2003. Comparison of the effects of acute influenza infection and influenza vaccination on HIV viral load and CD4 cell count. J. Clin. Virol. 26:307-315.
42. Smith, N. M., J. S. Bresee, D. K. Shay, T. M. Uyeki, N. J. Cox, and R. A. Strikas. 2006. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 55(RR-10):1-42.
43. Sorvillo, F. J., and B. L. Nahlen. 1995. Influenza immunization for HIV-infected persons in Los Angeles. Vaccine 13:377-380.
44. Squarcione, S., S. Sgricia, L. R. Biasio, and E. Perinetti. 2003. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21:1268-1274.
45. Staprans, S. I., B. L. Hamilton, S. E. Follansbee, T Elbeik, P. Barbosa, R. M. Grant, and M. B. Feinberg. 1995. Activation of virus replication after vaccination of HIV-1-infected individuals. J. Exp. Med. 182:1727-1737.
46. Sullivan, P. S., D. L. Hanson, M. S. Dworkin, J. I. Jones, J. W. Ward, and the Adult and Adolescent Spectrum of HIV Disease Investigators. 2000. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 14:2781-2785.
47. Vu, T., S. Farish, M. Jenkins, and H. Kelly. 2002. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20:1831-1836.
48. Wodarz, D., and V. A. Jansen. 2001. The role of T cell help for anti-viral CTL responses. J. Theor. Biol. 211:419-432.
49. Wood, J. M., R. W. Newman, and K. Ploss. 2003. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev. Biol. (Basel) 115:9-16.
50. Wood, J. M., K. G. Nicholson, I. Stephenson, M. Zambon, R. W. Newman, D. L. Major, and A. Podda. 2002. Experience with the clinical development of influenza vaccines for potential pandemics. Med. Microbiol. Immunol. (Berlin) 191:197-201.
51. Yamanaka, H., K. Teruya, M. Tanaka, Y. Kikuchi, T. Takahashi, S. Kimura, S. Oka, and HIV/Influenza Vaccine Study Team. 2005. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 39:167-173.
52. Zanetti, A., A. Amendola, S. Besana, A. Boschini, and E. Tanzi. 2002. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 20:B29-B32.
53. Zuccotti, G. V., A. Zenga, P. Durando, L. Massone, B. Bruzzone, and D. Sala. 2004. Safety and immunogenicity of a trivalent virosomal influenza vaccine in a cohort of HIV-infected children. J. Int. Med. Res. 32:492-499.